Norway Model Offers Key To Unlock More Complex Switches
Executive Summary
Norway's move to encourage more innovative Rx-to-OTC switches has begun to bear fruit with the recent reclassification of Pfizer's Viagra. The country's decision to introduce a new non-prescription drug category to promote switching can be used as a model for securing a new wave of more complex switches elsewhere around the world.
You may also be interested in...
Sweden’s Proposal For New OTC Category Could Facilitate Switch
A more favorable environment for Rx-to-OTC switch could be one of the benefits of a proposal to introduce a new OTC classification in Sweden. The government has asked national regulator Läkemedelsverket to investigate how a pharmacist-only category of OTC drugs would work in practice.
Australia Introduces ‘Appendix M’ Criteria To Facilitate Innovative Switches
Australia's Therapeutic Goods Administration has introduced a set of criteria introducing additional controls for medicines rescheduled from ‘Schedule 4’ (prescription-only) to ‘Schedule 3’ (non-prescription, pharmacist-only) status, intended to facilitate more innovative prescription-to-OTC switches in the future.
Pfizer Building Viagra As Pan-European Consumer Health Brand With Rx-To-OTC Switch In Norway
Pfizer has taken the first steps towards turning its Viagra erectile dysfunction treatment into a pan-European OTC brand by taking advantage of Norway's new "non-prescription medicines with guidance" category to secure the Rx-to-OTC switch of the product. Norway will be the second European market where Viagra is available OTC after the UK switched the drug in 2017.